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ABSTRACT 
 
Background: The pathogenesis of pre-eclampsia as a primary cause of mortality among pregnant 
women remains unclear. It was suggested that angiogenic factors such as Soluble fms-Like 
Tyrosine Kinase-1 (SFLT-1) play an important role in the causal mechanism of pre-eclampsia/ 
eclampsia. This study aimed to compare the SFLT-1 level in pre-eclampsia/ eclampsia in pregnant 
women with that in normotensive pregnant women. 
Subjects and Method: This was an analytic observational conducted at three hospitals: Haji 
Adam Malik, Pirngadi, and Sundari Hospitals, Medan, Indonesia, from September to December 
2014. A total sample of 60 pregnant women of the third trimester, including those with severe pre-
eclampsia/ eclampsia and normotensive women, was selected for this study. The level of serum 
SFLT-1 was measured by ELISA method. The difference in mean of serum SFLT-1 levels between 
the two groups was tested by Mann-Whitney. 
Results: The mean of serum SFLT-1 level in women with preeclampsia was higher 
(mean=1692.69pg/ ml; SD=540.64) than that in normotensive women (mean=1348.52pg/ ml; 
SD=649.83). This difference was statistically significant (p=0.040). 
Conclusion: Level of serum SFLT-1 in women with severe pre-eclampsia/ eclampsia is 
significantly higher than that of normotensive women. 
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BACKGROUND 
 
The high maternal mortality rate is consider-
ed as one of the world’s health problems. 
Maternal mortality rate in developing count-
ries is 15 times higher than in developed 
countries (WHO, 2012). Indonesia as one of 
the developing countries still contributes in 
high maternal mortality rate. In the past 
five years, the rate of maternal mortality in 
Indonesia is increasing (BKKBN, 2012).  
As much as 24% of cases that cause 
maternal death is pre-eclampsia (Kemen-
kes, 2010). Around 10 of pregnancies world-
wide are associated with pre-eclampsia 
(WHO, 2011). In Indonesia, pre-eclampsia 
cases happen to 5-10% of the number of 
pregnancies (Kemenkes, 2011). According 
to North Sumatra Health Office data (2011), 
maternal mortality rate as the result of pre-
eclampsia in Pirngadi General Hospital Me-
dan, during 2008-2010 is increasing. 
Up to currently the pathogenesis of 
pre-eclampsia is not yet clearly discovered. 
There are a lot of theories state that there is 
a relationship between pre-eclampsia with 
placentation process. Cytotrophoblast cell 
which fails to invade spiral artery of a mo-
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their lead to the emergence of trophoblast 
injury and placental ischemia (Wang et al., 
2009). Ischemic placenta is predicted secret-
ing a factor of anti-angiogenic soluble fms 
Like Tyrosine Kinase-1 (SFLT-1) and after-
ward blood vessel endothelium is obstruct-
ed in performing angiogenesis. Placenta of 
pre-eclampsia patients produces SFLT-1, an 
anti-angiogenic factor  which obstructs ang-
iogenesis process by binding proangiogenic 
compound, among others are Vascular En-
dothelial Growth Factor (VEGF) and Pla-
cental Growth Factor (PLGF) (Andraweera 
et al., 2012; Wang et al., 2008; Mutter and 
Karumanchi, 2008). As the result of pla-
cental ischemia, dysfunction of endothel-
ium occurs. Endothelium dysfunction mani-
fests in a form of tissue damage and multi-
ple organs damage on mother and fetus 
which is progressive in nature (Karumanchi 
et al., 2007; Wang et al., 2009; Murphy et 
al., 2013). 
Numerous studies are emerging about 
how the level of angiogenesis factors is on 
pregnant women with pre-eclampsia. Im-
balance between angiogenic and antiangio-
genic in maternal circulation is considered 
contribute in severe pre-eclampsia patho-
physiology (Maynard et al., 2003; Eiland, 
2012) Some studies also stated that SFLT-1 
in serum is found  on pregnant women with 
pre-eclampsia in the early stage of pregnan-
cy up to the middle stage (Kusanovic, 2009; 
Yu et al., 2010). Compared to normal preg-
nancy, the level of sFLT-1 is higher in 
serum of women with pre-eclampsia (Le-
vine, 2004; Verlohren, 2012)   
The study aims to compare the level 
sFLT-1 on women with severe pre eclampsia/ 
eclampsia and normal pregnant women. 
 
SUBJECTS AND METHOD 
 
The study was analytical study by using 
matched case control design. Sample of the 
study was women with intrauterine preg-
nancy, living and single fetus, with gestat-
ional age was more than 28 weeks, who was 
diagnosed with or without severe pre-
eclampsia/ eclampsia by Obstetrician and 
Gynecologist of Haji Adam Malik Hospital 
Medan, Dr. Pirngadi Hospital, Sundari Ge-
neral Hospital Medan and recorded as pa-
tients in their status cards. The study ex-
cluded pregnant women who had history of 
diabetes mellitus, kidney abnormalities, 
history of heart disease, immunity devian-
ce, and pregnancies associated with co-
ngenital disorder on fetus. 
Sixty research samples were collected 
by consecutive method and divided into 2 
groups that were 30 case samples (group of 
pregnant women with severe pre-eclamp-
sia/ eclampsia) and 30 of control samples 
(group of women with normal pregnancy). 
During sample collection, matching process 
was conducted between case group and 
control group in the terms of maternal age, 
gestational age, and parity status.  
The study had obtained approval from 
Health Research Ethics Committee of Facul-
ty of Medicine, North Sumatra University  
(Inform Consent). 
 SFLT-1 level in blood serum was mea-
sured in Spectrum International laboratory 
Medan by using quantitative sandwich en-
zyme immuno assay method. 
The obtained data would be edited, 
coded, and afterward recorded into comput-
er. Initially, Kolmogorov-smirnov normality 
test was conducted on numerical data, it 
was continued with univariate analysis. 
Mann Whitney was used to know the com-
parison of SFLT-1 level on both groups  
  
RESULTS 
 
Characteristics of Patients 
Respondents of the study were women in 
the third semester of pregnancy, who were 
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divided into two groups, among others were 
30 pregnant women with severe pre-
eclampsia and the others were 30 women 
with normal pregnancy as control group. 
Matching process was conducted on both 
groups in the terms of age, gestational age, 
parity status. The most range of age of the 
respondents was 20-35 years old (83.3%), 
with the most gestational age ranged from 
37-38 weeks (50%) and the parity status 
was nulliparous women (46.7%). 
 
Table 1. Sample characteristics  
Characteristics Pre-eclampsia 
/eclampsia 
 Normal Pregnancy Group 
n %  n % 
Sample 
 20-35 years 
 > 35 years 
Pregnancy age  
 28-32 week 
 33-34 week  
 35-36 week 
 37-38 week 
Parity Status 
 Nulliparous 
 Primiparous 
 Multiparous 
 
25 
5 
 
2 
2 
11 
15 
 
 
14 
6 
10 
 
83.3 
16.7 
 
6.7 
6.7 
36.7 
50.0 
 
 
46.7 
20.0 
33.3 
  
25 
5 
 
2 
2 
11 
15 
 
 
14 
6 
10 
 
83.3 
16.7 
 
6.7 
6.7 
36.7 
50.0 
 
 
46.7 
20.0 
33.3 
 
Table 2 presents that the mean value of 
SFLT-1 level on group of women with se-
vere pre-eclampsia/ eclampsia is 1692.69 
pg/ ml.  Data of SFLT-1 level is data which 
is not normally distributed based on Kol-
gorov-smirnov normality test therefore the 
medium value of SFLT-1 level is presented. 
The study result shows that medium value 
of SFLT-1 level on group of pregnant wo-
men with severe pre-eclampsia/ eclampsia 
is as much as 1901.94pg/ ml whereas on 
group of women with normal pregnancy is 
1474.05 pg/ ml. 
 
Table 2. SFLT-1 level characteristics 
Variables  n Min  Max  Mean Standard 
Deviation  
p 
SFLT-1 (pg/ml) 
- Normal pregnancy 
- Pre-eclampsia/ 
eclampsia 
60 
30 
 
30 
16.26 
16.26 
 
181.84 
2077.60 
2054.72 
 
2077.60 
1520.61 
1348.52 
 
1692.69 
617.53 
649.83 
 
540.64 
0.040 
 
Comparison of  SFLT-1 Level 
Based on Figure 1 it can be seen that SFLT-
1 level on  group of pregnant women with 
severe pre-eclampsia/eclampsia is higher 
than on group of women with normal preg-
nancy. Mann-Whitney test result shows that 
SFLT-1 level on group of pregnant women 
with severe pre-eclampsia/ eclampsia is 
significantly higher compared to group of 
women with normal pregnancy (p=0.044). 
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* Significant by Mann-Whitney test 
Figure 1. Comparison Chart levels of SFLT-1 
 
DISCUSSION 
 
In this study, the most characteristic of 
pregnant women with pre-eclampsia/ ec-
lampsia was in 20-35 year old age group. 
The study of Kashanian et al (2011) in Iran 
stated that the most characteristic of preg-
nant women with pre-eclampsia/ eclampsia 
was in 20-30 years old of age. Kashanian et 
al., also stated that pregnant women who 
are more than 30 years old have bigger risk 
to endure pre-eclampsia than younger 
pregnant women. It is also in accordance 
with the study that stated that the older a 
woman then she will endure the higher 
risks to childbirth complications, one of 
them is pre-eclampsia (Jacobbson, 2004).   
The study showed  that most of the 
samples were nulliparous. It is in accord-
ance with the study which states that one of 
the risk factors for pre-eclampsia was the 
nulliparous status on women (Odegard, 
2000). 
In this study it obtained the mean 
value of SFLT-1 level on group of pregnant 
women in the third trimester with pre-
eclampsia/ eclampsia was 1692.69 pg/ml 
whereas on group of women with normal 
pregnancy was 1348.52 pg/ml. In this study 
it also obtained the medium value of SFLT-
1 level on group of pregnant women in the 
third trimester with severe pre-eclampsia/ 
eclampsia was 1901.935 pg/ ml whereas on 
group of women with normal pregnancy 
was 1474.05 pg/ ml. The result of Mann-
Whitney test showed that the level of SFLT-
1 on pregnant women with severe pre-
eclampsia/ eclampsia was significantly high-
er that on group of women with normal 
pregnancy (p =0.044).   It is in accordance 
with a study which states that there is a 
significant difference between the level of 
SFLT-1 on pre-eclampsia pregnant women 
with normal pregnant women (Maynard, 
2003; Levine et al., 2004; Widmer et al, 
2007).  Levine et al., states that the average 
rise of SFLT-1 level on pre-eclampsia es-
calates up to three times than the value on 
normal pregnant women. The escalation 
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happens after the 25th week of pregnancy 
(Widmer et al., 2007).       
The level of SFLT-1 on normal preg-
nant women will start to increase in the 
20th-30th week of pregnancy and later will 
rapidly escalate in the 35th-39th week of 
gestation age. However the increasing of 
SFLT-1 on group of pregnant women with 
pre-eclampsia happens bigger than normal 
pregnant women (Levine, 2004). SFLT-1 as 
antiangiogenic factor is found more in pla-
centa and serum of pregnant women with 
pre-eclampsia (Maynard, 2003). On preg-
nant women with pre-eclampsia there is 
found placenta which endures ischemia. 
The ischemic placenta produces more 
SFLT-1 (Smith and Wear, 2009). Masa-
bumi (2012) conveys that hypoxia condit-
ion found in pre-eclampsia placenta have 
significant effect in SFLT-1 regulation. The 
reduction of utero-placenta blood stream 
leads to the rise of SFLT-1 ekspression. It is 
predicted there is HIF-1α contribution in 
the rise of SFLT-1. Hypoxia condition on 
placenta stimulates the activity of HIF-1α, 
afterward HIF-1α increase the expression 
and secretion of SFLT-1 (Zhou et al., 2011).    
High level of SFLT-1 on the circulat-
ion hampers the work of pro-angiogenic 
factors (Levine, 2004; Matsubara, 2009). 
The imbalance angiogenic leads to endo-
thelium dysfunction. The condition gene-
rates the emergence of clinical manifestat-
ion such as hypertension, coagulation dis-
order and proteinuria. It probably may 
explain pathophysiology of clinical manifest-
ation which emerges on severe pre-eclamp-
sia/ eclampsia.  
The conclusion derived from the stu-
dy was that SFLT-1 level in group of preg-
nant women with pre-eclampsia was higher 
than on group of normal pregnant women. 
The study was narrowly conducted on 
women in the third trimester of their preg-
nancy therefore the level of SFLT-1 obtain-
ed was the illustration of pre-eclampsia 
occurrence process. It is expected to cond-
uct further study by observing the changes 
of SFLT-1 level from the second trimester 
up to the end of the pregnancy and obtain 
screening value toward the clinical symp-
toms deterioration as the result of pre-
eclampsia. Eventually a management can be 
conducted in preventing the deterioration 
as the result of pre-eclampsia from prenatal 
period, thus will give value in the effort to 
suppress maternal mortality rate. 
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